Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development
Palvella Therapeutics Awarded Up to $2.6 million Grant
top of page
Search
Press Release
Apr 17
Avive Solutions Raises $56.5M
Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in...
Press Release
Jan 8
Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market
SOUTHLAKE, Texas, Jan. 8, 2024 /PRNewswire/ -- Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations...
AOA Dx LinkedIn News
Nov 1, 2023
AOA Dx News Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test
Liquid biopsy startup AOA Dx has collected $17 million to support the development of its diagnostic test for ovarian cancer...
Press Release
Jul 27, 2021
AMWELL Enhances Virtual Care Platform with Two Acquisitions: SilverCloud Health and Conversa Health
Transactions Advance Amwell’s Strategy to Enable Health Systems’ and Health Plans’ Telehealth Programs with Ongoing Organic and Inorganic...
The Silicon Review
Jul 13, 2021
The Silicon Review names Conversa as one of the 50 Fastest Growing Companies in the Year 2021
Titled "A Game-Changer: Conversa Health’s Automated Virtual Care Platform was Built to Support the Hybrid-Care Model of the Future" the...
Gore Range Capital
Mar 9, 2021
Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal
Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd.
Gore Range Capital
Jan 19, 2021
Automated Virtual Care Platform Conversa Health Expands Series B to $20 Million
Conversa Health, a leading virtual care and triage platform, has expanded its Series B financing to $20 million
Gore Range Capital
Apr 10, 2020
Maternity management company Dorsata scores $5.2M in Series A funding
Women’s Health USA, QED Investors, LabCorp, Fool Ventures and Gore Range Capital participated in this round.
Gore Range Capital
Sep 30, 2019
Or-Genix Therapeutics Inc. and Fission Labs Announce Partnership for LATAM Dermatology Markets
WORCESTER, Mass.--(BUSINESS WIRE)-- Or-Genix Therapeutics, Inc., a development-stage specialty woman’s health and dermatology company,...
Gore Range Capital
Jul 24, 2019
Castle Biosciences Announces Pricing of Initial Public Offering
Castle Biosciences, Inc. announced today the pricing of its IPO of 4,000,000 shares of its common stock at a price of $16/share
Gore Range Capital
Jul 8, 2019
Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer
Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer
Gore Range Capital
Jun 26, 2019
Genomic diagnostics provider Castle Biosciences files for a $58 million IPO
Castle Biosciences filed on Wednesday with the SEC to raise up to $58 million in an initial public offering.
bottom of page